Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)
Others
Ratios

Tvardi Therapeutics (TVRD) Operating Expenses (2016 - 2025)

Tvardi Therapeutics' Operating Expenses history spans 13 years, with the latest figure at $7.6 million for Q4 2025.

  • On a quarterly basis, Operating Expenses fell 29.76% to $7.6 million in Q4 2025 year-over-year; TTM through Dec 2025 was $27.3 million, a 50.69% decrease, with the full-year FY2025 number at $26.7 million, down 4.84% from a year prior.
  • Operating Expenses hit $7.6 million in Q4 2025 for Tvardi Therapeutics, up from $5.9 million in the prior quarter.
  • Over the last five years, Operating Expenses for TVRD hit a ceiling of $39.3 million in Q2 2023 and a floor of $5.0 million in Q1 2025.
  • Historically, Operating Expenses has averaged $23.3 million across 5 years, with a median of $29.2 million in 2021.
  • Biggest five-year swings in Operating Expenses: soared 61.98% in 2022 and later tumbled 84.42% in 2025.
  • Tracing TVRD's Operating Expenses over 5 years: stood at $34.3 million in 2021, then rose by 0.66% to $34.6 million in 2022, then increased by 3.02% to $35.6 million in 2023, then plummeted by 69.67% to $10.8 million in 2024, then fell by 29.76% to $7.6 million in 2025.
  • Business Quant data shows Operating Expenses for TVRD at $7.6 million in Q4 2025, $5.9 million in Q3 2025, and $8.9 million in Q2 2025.